Tesamorelin 5mg GHRH analog research peptide

Tesamorelin GHRH analog: a research overview

Tesamorelin is one of the few GHRH analogs with a current FDA approval. Here's a peaceful walk through the trials that got it there.

Please note: Snowman Research does not offer dosing information or usage guidance of any kind. Everything we list, this item included, is sold strictly for research purposes and nothing else.

Published findings

Tesamorelin's research record includes several randomized trials in people living with HIV. In a 26-week study in NEJM (2007), visceral fat decreased 15.2% with tesamorelin and increased 5.0% with placebo; lipids improved and IGF-I rose by 81% ^[1]. When investigators combined data from two phase 3 trials (The Journal of Clinical Endocrinology & Metabolism, 2010), the drop in visceral fat persisted through week 52, and glucose measures did not shift in a clinically meaningful way ^[2]. In 2019, a Lancet HIV trial of 61 participants with HIV and non-alcoholic fatty liver disease reported a 37% relative drop in liver fat fraction compared with placebo ^[3].

Mechanism at a glance

Chemically, tesamorelin belongs to the GHRH-analogue family; its prescribing label describes it as an analog of growth hormone-releasing factor ^[4]. Its pivotal trial tracked a large climb in IGF-I relative to placebo ^[1].

Regulatory & WADA notes

Tesamorelin received its first U.S. approval in 2010. Today's labeling (EGRIFTA WR) confines it to a single use, trimming excess abdominal fat in adults with HIV and lipodystrophy, and says plainly that it isn't meant for weight-loss management ^[4]. This research material is distinct from that approved medicine. Athletes should note that tesamorelin is listed by name in section S2.2.4 of WADA's 2026 List, a class banned at all times ^[5].

Thanks for reading. Stay warm, and keep your bench notes tidy.

Further reading

1. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. PMID 18057338. https://pubmed.ncbi.nlm.nih.gov/18057338/
2. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304. PMID 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/
3. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PMID 31611038. https://pubmed.ncbi.nlm.nih.gov/31611038/
4. DailyMed - EGRIFTA WR- tesamorelin kit. EGRIFTA WR prescribing information, DailyMed (U.S. National Library of Medicine). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75
5. World Anti-Doping Code International Standard: Prohibited List 2026 (in effect 1 January 2026). World Anti-Doping Agency, 2026 Prohibited List. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

For laboratory research use only. This product is not intended for human or veterinary use and is not an FDA-approved drug; nothing on this page is medical advice. You must be 21 or older to purchase.